相关实验视频

Updated: May 3, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

免疫检查点抑制剂和免疫媒介不良事件的风险:一项队列研究,比较延长与标准间隔的治疗时间

Amélia Lessard-Roy^1,2, Roxanne Marchand^1,3, Pierre Lemieux^4,5

¹Faculté de Pharmacie, Université Laval, Québec, QC, Canada.

Clinical and experimental medicine

|February 22, 2024

概括

扩展间隔免疫检查点抑制剂 (ICI) 与瘤门诊患者的标准间隔一样安全. 这项研究发现,标准和扩展ICI剂量表之间的免疫媒介不良事件 (IMAE) 没有显著差异.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

由于COVID-19大流行,免疫检查点抑制剂 (ICI) 的剂量间隔延长,以减少医院访问.
有限的数据存在于延长间隔ICI的安全性.

研究的目的:

在接受标准与延长间隔ICI的瘤门诊患者中比较免疫媒介不良事件 (IMAE).
分析IMAE发病率,严重程度和时间的差异.

主要方法:

在2015年至2021年期间接受ICI的310名患者的回顾性队列研究.
从患者记录和药房软件中收集的数据.
使用调整后勤,Poisson和Cox回归模型进行统计分析.

主要成果:

在标准间隔和扩展间隔组之间,IMAE总数,发病率或严重程度没有统计学上显著的差异.
每位参与者的平均IMAE:1.02 (标准) 与1.18 (扩展).
第一次IMAE的调整危险比为0.92 (95% CI 0.67-1.26) 延长与标准间隔.

结论:

在瘤门诊患者中,延长间隔ICI的使用与标准间隔的使用一样安全.
延长剂量不会增加IMAE的风险.

关键词:

延长的间隔时间免疫检查点抑制剂免疫检查点抑制剂免疫介导的不良事件免疫治疗是一种免疫疗法.安全的安全的安全的安全的安全.标准区间是标准区间.

更多相关视频

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.